Lexatumumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TRAIL-R2 |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 845816-02-6  |
| ATC code | None |
| UNII | 967Q0SJD77  |
| KEGG | D06611 |
| Chemical data | |
| Formula | C6346H9832N1720O2002S42 |
| Mol. mass | 143.6 kDa |
 (what is this?) (verify) |
|
Lexatumumab (also known as ETR2-ST01) is an agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) used in the treatment of cancer.[1]
HGS-ETR2 antibodies were generated by HGS through a collaboration with Cambridge Antibody Technology.[2]
[edit] References
- ^ Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab, American Medical Association.
- ^ http://www.hgsi.com/trail-receptor-antibodies-5.html
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
